Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.statnews.com/2023/10/30/sareptas-duchenne-gene-therapy-fails-to-meet-primary-endpoint-in-pivotal-trial/
0
0
Sarepta's Duchenne gene therapy fails to meet primary endpoint in pivotal trial - STAT
10/30/23 at 8:36pm
Organization
STAT
Authors
Jason Mast
Adam Feuerstein
Details
41 words
Summarize
Business & Industrial
Health Conditions
DMD
Sarepta
STAT Sarepta Therapeutics
Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial.
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...